Novel molecular screening approaches in colorectal cancer

Journal of Surgical Oncology

Volumn 105, Issue 5, 2012, Pages 459-467

  Miller, Seth ^a   Steele, Scott ^a  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

colorectal cancer (CRC); molecular screening

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; APC PROTEIN; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; CYTOSINE; DNA; ESTROGEN RECEPTOR BETA; INDUCIBLE NITRIC OXIDE SYNTHASE; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; PROTEIN MLH1; PROTEIN P16; PROTEIN P53; RETINOID X RECEPTOR ALPHA; SECRETED FRIZZLED RELATED PROTEIN 2; STAT3 PROTEIN;

BARIUM ENEMA; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CARDIOPULMONARY INSUFFICIENCY; COLON DISEASE; COLON DIVERTICULOSIS; COLON HEMORRHAGE; COLON PERFORATION; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COST EFFECTIVENESS ANALYSIS; DNA METHYLATION; DNA SCREENING; DOUBLE CONTRAST BARIUM ENEMA; DOWN REGULATION; EARLY DIAGNOSIS; EPIGENETICS; FECES ANALYSIS; FLEXIBLE SIGMOIDOSCOPY; HUMAN; IMMUNOCHEMISTRY; MOLECULAR DIAGNOSIS; OCCULT BLOOD TEST; POSTPOLYPECTOMY SYNDROME; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY;

COLONOGRAPHY, COMPUTED TOMOGRAPHIC; COLONOSCOPY; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; DOWN-REGULATION; EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; FECES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASS SCREENING; MICRORNAS; NEOPLASM STAGING; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84859055066     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21704     Document Type: Review

References (95)

1. SEER Stat Fact Sheet; colon and rectum. National Cancer Institute. (Accessed December 14, 2009).
2. Hofstad B, Vatn M,: Growth rate of colon polyps and cancer. Gastointest Endosc Clin N Am 1997; 7: 345-363. (Pubitemid 27317339)
3. Winawer SJ, Fletcher RH, Miller L, et al.: Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997; 112: 594.
4. Wong JL, Hawkins NJ, Ward RL,: Colorectal cancer: A model for epigenetic tumorigenesis. Gut 2007; 56: 140-148. (Pubitemid 46044900)
5. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627.
6. Levin B, Lieberman DA, McFarland B, et al.: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58: 130.
7. Rex DK, Johnson DA, Anderson JC, et al.: American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol 2009; 104: 739.
8. Use of colorectal cancer tests United States, 2002, 2004, 2006. MMWR Morb Mortal Wkly Rep 2008; 57: 253.
9. Ho JM, Juurlink DN, Cavalcanti RB,: Hypokalemia following polyethylene glycol-based bowel preparation for colonoscopy in older hospitalized patients with significant comorbidities. Ann Pharmacother 2010; 44: 466-470.
10. Beloosesky Y, Grinblat J, Weiss A, et al.: Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med 2003; 163: 803-808. (Pubitemid 36438052)
11. Ell C, Fischbach W, Keller R, et al.: A randomized, blinded, prospective trial to compare the safety and efficacy of three bowel-cleansing solutions for colonoscopy (HSG-01*).
12. Allison JE, Tekawa IS, Ransom LJ, et al.: A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155-159. (Pubitemid 26017953)
13. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al.: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-2714. (Pubitemid 39665324)
14. Hardcastle JD, Chanberlain JO, Robinson MH, et al.: Randomized controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477. (Pubitemid 26400242)
15. Kronborg O, Fenger C, Olsen J, et al.: Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471. (Pubitemid 26400241)
16. Wilson JM, Junger G,: Principles and practice of screening for disease. Geneva, Switzerland: World Health Organization; 1968.
17. Gopalswanny N, Stelling HP, Markert RJ, et al.: A comparative study of eight fecal occult blood tests and HemoQuant in patients in whom colonoscopy is indicated. Arch Fam Med 1994; 3: 1043-1048.
18. Greenberg PD, Bertario L, Gnauk R, et al.: A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000; 95: 1331-1338. (Pubitemid 30263533)
19. Levi Z, Rozen P, Hazazi R, et al.: A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-255. (Pubitemid 351650610)
20. Smith A, Young GP, Cole SR, et al.: Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006; 107: 2152-2159. (Pubitemid 44665648)
21. Wong BC, Wong WM, Cheung KL, et al.: A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther 2003; 18: 941-946. (Pubitemid 37346679)
22. Morikawa T, Kato J, Yamiji Y, et al.: A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-428. (Pubitemid 41096630)
23. Seef LC, Richards TB, Shapiro JA, et al.: How many endoscopies are performed for colorectal cancer screening? Results from CDC's, survey of endoscopic capacity. Gastroenterology 2004; 127: 1670-1677. (Pubitemid 39575845)
24. Muller AD, Sonnenberg A,: Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 1995; 123: 904-910.
25. Winawer SJ, Zauber AG, Ho MN, et al.: Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981. (Pubitemid 24015040)
26. Imperiale TF, Wagner DR, Lin Cy, et al.: Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169-174. (Pubitemid 30489213)
27. Lieberman DA, Weiss DG, Bond JH, et al.: Use of colonoscopy to screen asymptomatic adults forcolorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-168. (Pubitemid 30489212)
28. Arora G, Mannalithara A, Singh G, et al.: Risk of perforation from a colonoscopy in adults: A large population-based study. Gastrointest Endosc 2009; 69: 654-664.
29. Levin TR, Zhao W, Conell C, et al.: Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006; 145: 880-886. (Pubitemid 351639963)
30. Ko CW, Riffle S, Michaels L, et al.: Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. Clin Gastroenterol Hepatol 2010; 8: 166-173.
31. Vining DJ,: Virtual endoscopy: Is it a reality? Radiology 1996; 200: 30.
32. Zauber AG, Levin TR, Jaffe CC, et al.: Implications of new colorectal cancer screening technologies for primary care practice. Med Care 2008; 46: 138-146.
33. Pickhardt PJ, Choi JR, Hwang I, et al.: Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349: 2191-2200. (Pubitemid 37485135)
34. Cotton PB, Durkalski VL, Pineau BC, et al.: Computed tomographic colonography (virtual colonoscopy): A multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004; 291: 1713-1719. (Pubitemid 38489893)
35. Mulhall BP, Veerappan GR, Jackson JL,: Meta-analysis: Computed tomographic colonography. Ann Intern Med 2005; 142: 635-650. (Pubitemid 40529961)
36. Johnson CD, Chen MH, Toledano AY, et al.: Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008; 259: 1207-1217.
37. Coady-Fariborzian L, Angel LF, Procaccino JA, et al.: Perforated colon secondary to virtual colonoscopy: Report of a case. Dis Colon Rectum 2004; 47: 1247-1249. (Pubitemid 38857080)
38. Kamar M, Portno O, Bar-Dayan A, et al.: Actual colonic perforation in virtual colonoscopy: Report of a case. Dis Colon Rectum 2004; 47: 1242-1246.
39. Atalla MA, Rozen WM, Master M, et al.: Colonic perforation during 'virtual' CT colonography. J Gastrohepatol 2009; 24: 1800.
40. 2 insufflation in an asymptomatic adult. Adom Imaging 2008; 33: 598-600.
41. Belo-Oliveira P, Curvo-Semedo L, Rodrigues H, et al.: Sigmoid colon perforation at CT colonography secondary to a possible obstructive mechanism: Report of a case. Dis Col Rectum 2007; 50: 1478-1480. (Pubitemid 47472404)
42. Khan JS, Moran BJ,: Iatrogenic perforation at colonic imaging. Colorectal Dis 2009; Dec 8 [Epub ahead of print].
43. Sosna J, Blachar A, Amitai M, et al.: colonic perforation at CT colonography: Assessment of risk in a multicenter large cohort. J Radiol 2006; 239: 457-463.
44. Veerappan GR, Cash BD,: Should computed tomographic colonography replace optical colonoscopy in screening for colorectal cancer? Pol Arch Med Wewn 2009; 119: 236-240.
45. Zitt M, Zitt M, Muller HM,: DNA methylation in colorectal cancer. Impact on screening and therapy monitoring modalities? Dis Markers 23: 51-71.
46. Fearon ER, Vogelstein B,: A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
47. Lengauer C, Kinzler KW, Vogelstein B,: Genetic instabilities in human cancers. Nature 1998; 396: 643-649. (Pubitemid 29003936)
48. Kinzler KW, Volgelstein B,: Lessons from hereditary colorectal cancer. Cell 1996; 97: 159-170. (Pubitemid 26358996)
49. Whitney D, Skoletsky J, Moore K, et al.: Enhanced retrival of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn 2004; 6: 386.
50. Ahlquist DA, Skoletsky JE, Boynton KA, et al.: Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget ass panel. Gastroenterology 2000; 119: 1219-1227.
51. Brand RE, Ross ME, Shuber AP,: Reproducibility of a multitarget stool-based DNA assay for colorectal cancer detection. Am J Gastroenterol 2004; 00: 1338-1341. (Pubitemid 39062273)
52. Calistri D, Rengucci C, Bocchini R, et al.: Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003; 3: 47-53.
53. Syngal S, Stoffel E, Chung D, et al.: Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer 2006; 106: 277-283. (Pubitemid 43100434)
54. Tagore KS, Lawson MJ, Yucaitis JA, et al.: Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 47-53. (Pubitemid 37220787)
55. Jensch S, Bipat S, Peringa J, et al.: CT colonography with limited bowel preparation: Prospective assessment of patient experience and preference in comparison to optical colonoscopy with cathartic bowel preparation. Eur Radiol 2010; 20: 146-156.
56. Gluecker TM, Johnson CD, Harmsen WS, et al.: Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: Prospective assessment of patient perceptions and preferences. J Radiol 2003; 227: 378-384. (Pubitemid 36514750)
57. Berger BM, Schroy PC, Rosenberh JL, et al.: Colorectal cancer screening using stool DNA analysis in clinical practice: Early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests. Clin Colorectal Cancer 2006; 5: 338-343. (Pubitemid 43280063)
58. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, et al.: Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Newtwork (CISNET) for MISCAn and SimCRC Models. Available at:. View 27 Jan 2010.
59. Iacopetta B,: Aberrant DNA methylation: Have we entered the era of more than one type of colorectal cancer? Am J Pathol 2003; 162: 1043-1045. (Pubitemid 36350649)
60. Gama-Sosa MA, Slagel VA, Trewyn RW, et al.: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983; 11: 6883-6894.
61. Goelz SE, Vogelstein B, Hamilton SR, et al.: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985; 228: 187-190. (Pubitemid 15117274)
62. Oberwalder M, Zitt M, Wontner C, et al.: SFRP2 methylation in fecal DNA. A marker for colorectal polyps. Int J Colorectal Dis 2008; 23: 15-19. (Pubitemid 350142355)
63. Grady WM, Rajput A, Lutterbaugh JD,: Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001; 61: 900-902. (Pubitemid 32174399)
64. Shapiro B, Chakrabarty M, Cohn EM,: Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983; 51: 2116-2120. (Pubitemid 13092467)
65. Nakayama H, Hibi K, Taguchi M,: Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett 2002; 188: 115-119. (Pubitemid 35292337)
66. Zou HZ, Yu BM, Wang ZW,: Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 2002; 8: 188-191.
67. Davies RJ, Miller R, Coleman N,: Colorectal cancer screening: Prospects for molecular stool analysis. Nat Rev Cancer 2005; 199-209. (Pubitemid 40314951)
68. Muller HM, Oberwalder M, Fiegl H, et al.: Methylation changes in faecal DNA: A marker for colorectal cancer screening? Lancet 2004; 363: 1283-1285. (Pubitemid 38496491)
69. Aslam MI, Taylor K, Pringle JH, et al.: MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 2009; 96: 702-710.
70. Janakiran NB, Rao CV,: Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin 2008; 29: 1-20.
71. Bartel DP, Chen CZ,: Micromanagers of gene expression: The potentially widespread influence of metazoan micro-RNAs. Nat Rev Genet 2004; 5: 396-400. (Pubitemid 38529411)
72. Hammond SM, Caudy AA, Hannon GJ,: Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001; 2: 110-119. (Pubitemid 33674002)
73. Denli AM, Tops BB, Plasterk RH, et al.: Processing of primary microRNAs by the microprocessor complex. Nature 2004; 432: 231-235. (Pubitemid 39545854)
74. Bircheler JA, Kavi HH,: Molecular biology. Slicing and dicing for small RNAs. Science 2008; 320: 1023-1024. (Pubitemid 351934163)
75. Bartel DP,: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
76. Berstein E, Caudy AA, Hammond SM, et al.: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-366. (Pubitemid 32151243)
77. Ahmed FE, Jeffries CD, Vos PW, et al.: Diagnostic MicroRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009; 6: 281-296.
78. Nagel R, le Sage C, Diosdado B, et al.: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008; 68: 5795-5802.
79. Slaby O, Svoboda M, Fabian P, et al.: Altered expression of MIR-21, miR-31, miR143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-402. (Pubitemid 351238155)
80. Monzo M, Navarro A, Bandres E, et al.: Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 2008; 18: 823-833.
81. Volinia S, Calin GA, Liu CG, et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci 2006; 103: 2257-2261. (Pubitemid 43271657)
82. Schetter AJ, Leung SY, Sohn JJ, et al.: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436. (Pubitemid 351185951)
83. Xi Y, Formentini A, Chien M, et al.: Prognostic values of microRNAs in colorectal cancer. Biomarker Insights 2006; 1: 113-121.
84. Cummins JM, He Y, Leary RJ, et al.: The colorectal microRNAome. Proc Natl Acad Sci 2006; 103: 3687-3692. (Pubitemid 43376616)
85. Faber C, Kirchner T, Hlubek F,: The impact of microRNAs on colorectal cancer. Virchows Arch 2009; 454: 359-367.
86. Dews M, Homayouni A, Yu D, et al.: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065.
87. Zhao HY, Ooyama A, Yamamoto M, et al.: Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. Cancer Lett 270: 156-163.
88. Michael MZ, O'Connor SM, Van Holst Peelekaan NG, et al.: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-891. (Pubitemid 37288707)
89. Bandres E, Cubedo E, Agirre X, et al.: Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29.
90. Chang TC, Wentzel EA, Kent OA, et al.: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752.
91. Lodygin D, Tarasov V, Epanchinstec A, et al.: Inactivation of miR-34a by aberrant CpG mehtylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
92. Ahmed FE, Vos P, James S, et al.: Transcriptomic molecular markers for screening human colon cancer in stool and tissue. Cancer Genomics Proteomics 2007; 4: 1-20. (Pubitemid 46426643)
93. Greenbaum D, Colangelo C, Williams K, et al.: Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003; 4: 117-126.
94. Lanza G, Ferracin M, Gafa R, et al.: mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007; 6: 54.
95. Mahgerefteh S, Fraifeld S, Blachar A, et al.: CT colonography with decreased purgation: balancing preparation, performance, and patient acceptance. AJR Am J Roentgenol 2009; 193: 1531-1539.